Cambridge Healthtech Institute’s Seventh Annual
Companion Diagnostics: Strategy & Partnerships
Strategy, Partnership, Technology and Adoption
August 23-24, 2016 | Grand Hyatt Hotel | Washington, DC
The co-development of drugs and diagnostics, i.e. companion diagnostics development, is delivering significant patient benefits, healthcare cost savings, and revenue opportunities. Historically it carries out most technological advances both as IVD products, and as laboratory developed tests with gene panels and even whole exome sequencing playing a role of companion tests. The space of companion diagnostics is highly sensitive to the regulatory and reimbursement fluctuations, and it requires specific market access strategies. Cambridge Healthtech Institute’s Seventh Annual Companion Diagnostics: Strategy & Partnerships conference is designed to facilitate knowledge and opinion exchange between pharmaceutical and diagnostics executives, translational scientists, clinicians, business experts, regulators, international companion diagnostics leaders, and other parties involved in drug-diagnostics co-development and precision medicine. Case studies of successful collaboration between pharmaceutical and diagnostics companies’ researchers and executives will be presented.
The meeting will cover a range of topics including:
- Collaboration between pharma and diagnostics in discovery, development and commercialization
- Integration of Rx and Dx development plans
- Case studies for successful pharma–diagnostics collaboration
- Various business models for pharma–diagnostics collaboration
- Strategies to increase the value for the diagnostic partners
- Pharmacogenomics and companion diagnostics in non-oncology TAs
- Pharma-diagnostics alliance management
- Co-commercialization of diagnostics and therapeutics
- Regulatory update: U.S. and international considerations
- Novel molecular technologies for companion diagnostics: development and implementation
- Co-development of drugs and multiplex companion diagnostics
- NGS-based assays to guide therapeutic decisions
- Diagnostics services in biomarker-driven clinical trials
- Large scale/population sequencing for biomarker identification
- Early vs. late stage drug/diagnostics co-development
Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality conference program.
If you are interested in presenting, please click here. Replies to proposals can take up to 8-12 weeks. We will notify you once the agenda has been finalized.
Deadline for submission is February 5, 2016.
We welcome your comments, suggestions and speaker suggestions as we shape the 2016 program.
For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Senior Director, Conferences
Cambridge Healthtech Institute
T: (+1) 781-972 5496
For exhibit & sponsorship opportunities, please contact:
Joseph Vacca, M.Sc.
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431